Literature DB >> 12003186

Phase II trial of amonafide in central nervous system tumors: a Southwest Oncology Group study.

Sarah A Taylor1, Cathryn Rankin, Jeannette J Townsend, Johnny B Craig, Ralph B Vance, Dilip L Solank, Thomas D Brown, Kurt Jaeckle.   

Abstract

Amonafide 300 mg/M2 was administered intravenously on a daily x 5 schedule to 27 eligible patients with recurrent or progressive central nervous system tumors. There were no objective responses. The most common toxicities were gastrointestinal, hematologic and neurologic. Further study of amonafide in patients with central nervous system malignancies is not indicated.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12003186     DOI： 10.1023/a:1014488922368

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  7 in total

1.  Intercalative binding to DNA of antitumour drugs derived from 3-nitro-1,8-naphthalic acid.

Authors:  M J Waring; A González; A Jiménez; D Vázquez
Journal:  Nucleic Acids Res       Date:  1979-09-11       Impact factor: 16.971

2.  Reporting results of cancer treatment.

Authors:  A B Miller; B Hoogstraten; M Staquet; A Winkler
Journal:  Cancer       Date:  1981-01-01       Impact factor: 6.860

3.  Amonafide as first-line chemotherapy for metastatic breast cancer.

Authors:  G Kornek; M Raderer; D Depisch; K Haider; B Fazeny; C Dittrich; W Scheithauer
Journal:  Eur J Cancer       Date:  1994       Impact factor: 9.162

4.  Phase II trial of amonafide in patients with advanced metastatic or recurrent endometrial adenocarcinoma. A Southwest Oncology Group study.

Authors:  V K Malviya; P Y Liu; R O'Toole; D S Alberts; E Surwit; S Rosenoff; J H Ward; A Yu; J O'Sullivan; J B Craig
Journal:  Am J Clin Oncol       Date:  1994-02       Impact factor: 2.339

5.  A randomized phase II trial of amonafide or trimetrexate in patients with advanced non-small cell lung cancer. A trial of the North Central Cancer Treatment Group.

Authors:  D H Gesme; J R Jett; D D Schreffler; J Q Su; J A Mailliard; J F Foley; J E Krook; A W Maksymiuk; A K Hatfield; L P Ebbert
Journal:  Cancer       Date:  1993-05-01       Impact factor: 6.860

6.  Phase I clinical investigation of benzisoquinolinedione.

Authors:  S S Legha; S Ring; M Raber; T B Felder; R A Newman; I H Krakoff
Journal:  Cancer Treat Rep       Date:  1987-12

7.  Phase II study of amonafide in patients with recurrent glioma.

Authors:  R Levitt; J C Buckner; T L Cascino; P A Burch; R F Morton; M W Westberg; R M Goldberg; J G Gallagher; J R O'Fallon; B W Scheithauer
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130
  7 in total
  1 in total

1.  Mode-of-action studies of the novel bisquaternary bisnaphthalimide MT02 against Staphylococcus aureus.

Authors:  Thomas M Menzel; Maximilian Tischer; Patrice François; Joachim Nickel; Jacques Schrenzel; Heike Bruhn; Annette Albrecht; Leane Lehmann; Ulrike Holzgrabe; Knut Ohlsen
Journal:  Antimicrob Agents Chemother       Date:  2010-10-11       Impact factor: 5.191
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.